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Targeting ferritin receptors for the selective delivery of imaging and therapeutic 
agents to breast cancer cells. 
S. Geninatti Cricha*, M. Cadenazzia, S. Lanzardoa, L. Contia, R. Ruiua, D. Albertia, F. Cavalloa, J.C. Cutrina, S. Aimea.  
Abstract. In this work the selective uptake of native horse spleen- ferritin and apoferritin loaded with MRI contrast agents have 
been assessed on human breast cancer cells (MCF-7, MDA-MB-231). The higher expression of L-ferritin receptors (SCARA5) let 
to an enhanced uptake in MCF-7 as shown in T2 and T1 weighted MR images, respectively. The high efficiency of ferritin 
internalization in MCF-7 has been exploited for the simultaneous delivery of curcumin, a natural therapeutic molecule endowed with 
antineoplastic and anti-inflammatory action, and the MRI contrast agent GdHPDO3A. This theranostic system is able to treat 
selectively breast cancer cells over-expressing ferritin receptors. By entrapping in apoferritin both Gd-HPDO3A and curcumin was 
possible to deliver a therapeutic dose of 97 g/ml (as calculated by MRI) of this natural drug into MCF-7 cells, obtaining a significant 
reduction of cell proliferation. 
  
 
 
Introduction. 
The incidence of breast cancer, the most common cancer in 
women and the second cause of cancer death in women 
worldwide1, is currently growing2. Three major therapeutic 
approaches are used today to treat breast cancer namely: surgical 
removal, irradiation, and chemotherapy. Anticancer treatments 
are based on three main approaches: (I) the classical 
chemotherapy, (II) hormone therapy (III) and the emerging and 
promising targeted therapy, where signalling pathways 
deregulated in primary breast tumours are specifically targeted. 
Breast cancer treatment is still challenging, as drugs in use have 
serious undesired effects, and drug resistance is common, 
underlying the need for new targeted therapies3. Accordingly, 
reduced adverse effects and better outcome were reported when 
targeted therapies were applied. Therefore, much attention is 
currently devoted, particularly in the field of nanotechnologies 
applied in medicine, to the targeting of precise alterations 
affecting the interactome, transcriptome, epigenome, and the 
receptome (a network of membrane transporters used by cancer 
cells) leading to the design of more specific tailored therapies. 
Recently, various systems, i.e. micelles, liposomes, 
biodegradable biopolymers and other nanoparticles loaded with 
contrast agents (CAs), have been proposed to noninvasively 
assess the accumulation at the target site of conjugated or co-
entrapped drugs, and to predict and monitor therapeutic 
responses4. This therapeutic and at the same time diagnostic 
(hereinafter referred as “theranostic”) approach appears to have 
a great potential providing highly specialized, more potent and 
safer tools to treat cancer5. The use of endogenous nanosized 
biomolecules for targeted cancer therapy is an interesting 
strategy to achieve this goal. Indeed, these molecules are ideal 
for the development of drug-delivery platforms, thanks to their 
biocompatibility and biodegradability. There are several 
examples in literature showing the potential of natural systems 
carrying CAs to detect diseases, some of them exploit ferritin 
cavity6. Ferritin is the main iron storage protein and is composed 
of 24 subunits of heavy (H)- or light (L)-chain peptides, that are 
present in different ratios in various organs, to form a cage 
architecture of 12 nm in external diameter with an interior cavity 
of 8 nm. Once deprived of iron, the inner cavity can be used as a 
universal drug delivery platform7. Several groups have 
functionalized the protein cage with specific ligands such as 
peptides (e.g. RGD)8, growth factors (e.g. EGF) 9, and biotin10 to 
improve its targeting capability. Recently, it was reported that H-
ferritin interacts with cells through the transferrin receptor11 
(TfR-1) and can be used to transport doxorubicin selectively to 
cancer cells overexpressing TfR-112. Herein, HoS-apoferritin 
(horse spleen apoferritin, 85 % and 15% L and H chains, 
respectively) is investigated for the simultaneous delivery of 
therapeutic and imaging agents (loaded into its internal cavity) 
to breast cancer cells by exploiting the L-ferritin transporting 
route without any further chemical functionalization of the 
protein surface. In fact, although L-ferritin functions are 
traditionally associated with intracellular iron storage, additional 
functions related to iron delivery based on a transferrin-
independent mechanism, to different target organs such as brain, 
liver and spleen have been recently discovered and 
investigated13. The involved receptors belong to the scavenger 
receptor class A member 5 (SCARA5)14 for L-ferritin and to 
TIM-215 and TfR-111 for H-ferritin, respectively. 
The relationship between ferritin and cancer arises from studies 
demonstrating an increase of the total ferritin (rich in L- chains) 
in the serum of patients with various malignancies16. However, 
the evaluation of L-ferritin levels in tumour tissue itself has 
revealed a complex, disease-specific picture. In some cases such 
as colon cancer, testicular seminoma, and breast cancer, the 
increase in L-ferritin level in tumour versus normal tissue has 
been reported17. In other cases, including liver cancer, a decrease 
in L-ferritin level has been observed17. In breast cancer patients, 
the available data shows that ferritin increase correlates with 
disease stage and that elevated serum concentration may be 
associated with local release within the breast tumor 
microenvironment. Moreover, breast tumor lysates also show 
elevated levels of L-ferritin, the predominant subunit observed 
in serum, and this increase correlates with advanced histological 
grade and shorter survival18. In this study, L-ferritin selective 
internalization has been investigated in breast cancer cells by 
MRI. Moreover, the apoprotein (apoferritin), obtained upon iron 
elimination from the cavity, was loaded with Mn ions or with 
Gd-based CAs and exploited for the simultaneous delivery of 
curcumin, a natural therapeutic molecule endowed with anti-
neoplastic and anti-inflammatory action19. Curcumin 
demonstrates anti-cancer activities both in vitro and in vivo by 
diverse mechanisms. It hinders proliferation and induces 
apoptosis in a wide range of cancer cell types in vitro, including 
breast, bladder, lung and other tissues20. Although clinical trials 
have demonstrated the safety of curcumin even at high doses 
(12g/day), the clinical advancement of this promising natural 
compound is hampered by its poor water solubility and short 
biological half-life. For these reasons, much attention has been 
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devoted to curcumin nanoformulations (liposomes, micelles, 
polymeric nanoparticles) developed to protect it from a fast 
degradation in aqueous solutions21. It has been already reported 
from our group that the encapsulation of curcumin inside the 
apoferritin cavity significantly increases its stability and 
bioavailability, while maintaining its therapeutic anti-
inflammatory properties in the attenuation of thioacetamide-
inducted hepatitis22. Although MRI sensitivity is lower in respect 
to nuclear and optical imaging modalities, the high spatial 
resolution (<100m) of MRI provides detailed morphological 
and functional information, and the absence of ionizing radiation 
makes it safer than techniques based on the use of radioisotopes. 
MRI signal is dependent on the longitudinal (T1) and transverse 
(T2) proton relaxation times of water and the endogenous 
contrast can be altered by the use of CA that decrease T1 and T2 
of water protons in the tissues where they distribute23. In a proton 
MR image there is a direct proportionality between the observed 
signal intensity enhancement and the concentration of the CA. 
Thus, these agents can be used to carry out indirect curcumin 
quantification upon their introduction in the apoferritin cavity. 
The aim of this study is the evaluation of the ferritin uptake and 
the efficacy of ferritin delivered antineoplastic compounds to 
cancer cells. For this purpose two human breast cancer cell lines, 
both expressing SCARA524, namely MDA-MB-231 and MCF-
7, were used.  
Results and Discussion.  
Horse spleen ferritin uptake.  
This study started with the evaluation of the ability of MCF-7 
and MDA-MB-231 cells to take up ferritin from the incubation 
media. To this purpose, horse spleen ferritin (HoS-ferritin) 
containing ca. 1000 iron atoms per protein, was used without 
further modification. The experimental protocol was based on 
the measurement of the amount of iron internalized by MCF-7 
and MDA-MB-231 cells, 6 and 24 hours upon incubation in the 
ferritin containing media, at 37°C and 5% CO2. The amount of 
internalized ferritin has been extrapolated by the ICP-MS 
determination of intracellular Fe content. After 6h incubation, 
differences between the two cell lines were evident (Figure 1). 
The amount of iron internalized by MCF-7 was significantly 
higher than in MDA-MB-231 cells and increased with ferritin 
concentration showing a saturating behaviour. To demonstrate 
the uptake specificity, competition assays were carried out by 
pre-incubating for 1.5h MCF-7 cells with free apoferritin. Then 
ferritin was added to the medium and after 6 hours incubation the 
amount of Fe taken-up by cells was measured by ICP-MS. The 
internalized ferritin decreased by about 40% when the 
concentration of apoferritin particles added to the culture 
medium was 7 and 15 fold excess (see supplementary). 
Ferritin contains a superparamagnetic ferrihydrite (5Fe2O39 
H2O) crystal which accelerates the transverse NMR relaxation 
(R2) of solvent water protons causing a negative  
 
 
Figure 1 Incubation of MDA-MB-231(○) and MCF-7 () cells 
with HoS-ferritin, for 6h (A) and 24h (B) at 37°C. After 
incubation cell lysates were analysed by ICP-MS to measure the 
amount of iron internalized by cells 
  
contrast in the corresponding images25. In fact, the presence of 
ferritin within tissues influences T2-weighted MRI signal 
intensity of liver, spleen, and brain, the organs where ferritin 
concentration is highest26. The effect of ferritin on MRI T2-
contrast increases to the magnetic field strength. Figure 2A 
shows the R2 values of a HoS-ferritin solution ([Fe]=100mM, 
loading factor=1000) measured at different magnetic fields. R2 
increased dramatically with the magnetic field strengths showing 
an enhanced sensitivity at high fields. Figure 2B reports the T2-
weighted MRI images of HoS-ferritin labelled MDA-MB-231 
and MCF-7 cells (5µM HoS-ferritin concentration in the 
incubation medium, 24h of incubation time). After incubation 
cells were washed, transferred into glass capillaries, and placed 
in agar phantom to acquire MR images at 7T. Cells incubated in 
the same medium without adding ferritin were used as a control. 
The T2-weighted RARE (TR/TE/NEX = 5000/53/4) image 
confirms that the ferritin induced contrast is markedly more 
efficient in MCF-7 cells with respect to MDA-MB-231. (Figure 
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2B). In fact, the signal intensity of MCF-7 cells incubated with 
ferritin is markedly lower than that observed in MDA-MB-231 
cells due to the negative contrast generated by ferritin. As 
expected, it was not possible to detect any difference in T- 
weighted images of the same ferritin treated cells. 
 
Figure 2 A) R2 of native HoS-ferritin measured at different 
magnetic field strengths (T=25°C). B) A representative T2-
weighted RARE MR image of agar phantoms containing (1) 
unlabeled MCF-7 cells; (2) MCF-7 incubated 24h with 5µM 
HoS-ferritin ; (3) unlabeled MDA-MB-231; (4) MDA-MB-231 
incubated 24h with (5µM) HoS-ferritin. 
 
Since negative contrast, generated in MR images may be affected 
by a number of uncontrolled conditions associated to local 
inhomogeneities in the specimen and in the magnetic field, the 
longitudinal relaxation time (T1) is considered the relaxation 
parameter that can be measured more accurately, and  
its value is less prone to be affected by uncontrolled experimental 
conditions. For this purpose apoferritin cavity was loaded with 
positive CAs such as Mn ions or a commercially available Gd-
complex. These molecules, characterized by a low R2/R1 ratio, 
are able to shorten T1 and the consequence is that cells where 
they are entrapped appear brighter in a T1 weighted image. Mn 
loaded apoferritin (Mn-Apo) is a highly sensitive MRI CA 
consisting of ca. 1000 manganese atoms entrapped in the inner 
cavity of apoferritin. The preparation of Mn-Apo was carried out 
following the reported procedure27 based on the dissolution of 
the previously formed -MnOOH inorganic phase performed via 
the reduction of Mn(III) to Mn(II) operated by 
aminopolycarboxylic acids that also act as sequestering agents 
for the weakly coordinated manganese ions on the outer surface 
of the protein (Figure 3). The reductive treatment yielded to the 
attainment of a MRI agent endowed with a remarkably high 
relaxivity value (per apoferritin) of about 7000mM –1 s–1. 
Cellular labelling experiments proved that after 24 hours of 
incubation in the presence of Mn-Apo (0.075 M protein 
concentration), the amount of internalized Mn was sufficient to 
 
Figure 3 Schematic representation of Mn-Apo preparation. 
 
generate hyperintense signals in MR images, recorded at 7T, of 
MCF-7 cells (Figure 4). The corresponding R1 of MCF-7 
increased proportionally with the concentration of Mn-Apo 
added to the medium and reached a plateau at concentrations 
higher than 0.075 μM (Figure 4). On the contrary, for MDA-MB-
231 the R1 values were markedly lower and constant, for all the 
Mn-Apo concentration range considered (Figure 4). 
 
 
Figure 4: A) T1-weighted MRI image of agar phantoms 
containing (1) unlabeled MCF-7 cells; (2) MCF-7 incubated 24h 
with (0.075 µM) Mn-Apo; (3) unlabeled MDA-MB-231; (4) 
MDA-MB-231 incubated with (0.075 µM)Mn-APO; B) 
Longitudinal relaxation rates (R1obs) measured on MCF-7 and 
MDA-MB-231 cell pellets. 
 
In order to prepare a theranostic system containing both a MRI 
CA and curcumin into the apoferritin cavity an alternative 
loading procedure22 was carried out exchanging Mn2+ ions with 
a Gd-based commercially available CA (Prohance). It is a neutral 
Gd complex well tolerated by cells and organisms. The loading 
procedure consists of lowering the pH of the apoferritin 
containing solution followed by the addition of the solutes to be 
uploaded28. The supramolecular structure of apoferritin collapses 
because of the rupture of the electrostatic interactions that 
maintain its spherical nanoarchitecture. When the pH is returned 
to 7 the spherical supramolecular shape of apoferritin (Gd-APO-
CUR) is restored with the entrapment of the desired solutes in its 
inner cavity. The number of molecules that remained entrapped 
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in the apoferritin upon the dissociation/reassociation procedure 
is 228 ± 48 and 9.6 ± 2 for curcumin and Gd-HPDO3A, 
respectively. 
Figure 5 shows the T1 weighted MR image measured on MCF-7 
and MDA-MB-231 cells incubated for 24h at 37°C in the 
presence of Gd-APO-CUR 1.3 and 2.7 M. The differences 
between the two cell lines that were observed with native HoS-
ferritin and Mn-Apo were reproduced also with this Gd-APO-
CUR preparation. By measuring the R1 of treated cells it was 
possible to calculate the intracellular Gd concentration by using 
the equation    
     
[Gd]mM =  (R1obs - R1d )/r1p(Gd-APO-CUR intra-cell)       Eq. 1                                                               
    
 
Figure 5. T1-weighted MRI image of agar phantoms containing 
unlabeled MDA-MB-231 cells (1); MDA-MB-231 incubated 24h 
with Gd-APO-CUR 1.3(2) and 2.7 (3)  M); unlabeled MCF-7 
(4); MCF-7 incubated with Gd-APO-CUR 1.3 (5) and 2.7 (6)  
M). 
 
In Equation (1), R1obs is the observed relaxation rate measured 
for each cell pellet at 7 T; R1d is the diamagnetic contribution to 
the observed relaxation rate measured in untreated cells; r1p (Gd-
APO-CUR intra-cell) is the intracellular millimolar relaxivity of 
the adduct (9.6 s-1mM-1). This value is significantly lower than 
that observed in water solution (r1p=17.7 mM-1s-1) as a 
consequence of the quenching effect due to the entrapment of the 
probe into endosomal/lysosomal vesicles. This was confirmed by 
assessing the intracellular distribution of the apoferritin particles 
after 24h incubation with MCF-7 by immunofluorescence using 
FITC- labelled apoferritin (APO-FITC). Figure S2, (supporting 
information) confirms that, at this time, most of the APO-FITC 
fluorescence was co-localized with lysosomes.”. 
Since the curcumin/Gd ratio in the apoferritin preparation was of 
24, an estimated intracellular curcumin concentration of 167 
μg/ml was obtained. In order to evaluate the cellular toxicity due 
to the presence of the Gd-HPDO3A complex in the theranostic 
probe, a batch of Gd-APO without curcumin was prepared using 
the same protocol reported above. Cell viability assessed using 
the trypan blue assay gave similar values of 88±3, 89±2 and 87±3 
% for cells untreated, treated with 1.3M and 2.7 M Gd-APO, 
respectively.  
 
SCARA5 detection.  
The observed difference in the ferritin uptake by MCF-7 and 
MDA-MB-231 cells suggests a different expression of ferritin 
receptors on these breast cancer cell lines. In order to get more 
insight into this issue, we examined the expression of the L-
ferritin receptor SCARA5 by immunofluorescence. The cells 
were seeded on glass coverslips and let to adhere on this substrate 
overnight at 37°C, 5% CO2. The day after, coverslips were fixed 
and stained for SCARA5 expression and visualized with 
fluorescent microscopy. Although both cell lines expressed 
SCARA5, they did it with a different distribution as showed in 
Figure 6. Whereas MCF-7 cells exhibited a diffuse 
plasmamembrane fluorescent pattern, MDA-MB-231 presented 
a unique positive speckle (Figure 6). This result is in line with 
the previously reported by Alkhateeb et all24, where SCARA5 
concentration, evaluated by western blotting assay, was higher in 
MCF-7 respect to MDA-MB-231. 
 
 
Figure 6 : SCARA5 staining of MCF-7 (A,C) and MDA-MB-231 
(B,D) plated on glass coverslips. Cells nuclei were counterstained 
with DAPI. Images were acquired with an Apotome fluorescent 
microscope (Leica), magnification x20(A,B) and x100 (C,D). 
Evaluation of curcumin and CUR-APO antiproliferative effect on 
MCF-7. 
Accordingly with the results reported above, proliferation assays were 
performed only on MCF-7 highly expressing SCARA5, by incubating 
cells in the presence of APO-CUR, free apoferritin and free curcumin 
(added as 6.2 mg/ml DMSO solution), at two different concentrations 
(50 and 100 , respectively). The absence of long term toxic effects 
associated with the presence of DMSO in the culture media was 
verified incubating MCF-7 cells with the highest DMSO 
concentration used (0.6%) (Figure 7). After incubation, cells were 
washed and protein concentration was measured with the Bradford 
assay. Since the number of cells is proportional to the protein 
concentration, this value has been converted in the corresponding cell 
number using a previously obtained calibration curve. Figure 7 shows 
that apoferritin alone did not affect cell proliferation as the obtained 
curve was similar to the control one. On the contrary, the proliferation 
rate of cells incubated with APO-CUR 50 μM and 100 μM (curcumin 
concentration) is significantly lower with respect to the control. As 
expected, the cytotoxic effect is proportional to the curcumin 
concentration and it is similar to that observed by incubating curcumin 
alone at the same concentrations. Furthermore, from these results it is 
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possible to confirm that the apoferritin cavity is able to protect 
curcumin from its degradation maintaining its pharmacological 
properties also if dissolved in an aqueous medium, where usually it is 
fastly degradated. 
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Figure 7: Incubation of MCF-7 for 24h with medium only () 
or in the presence of: DMSO 0.6% (○) apoferritin 0.5 M (), 
Apo-CUR 50 (▲) and 100 (▼) M (curcumin concentration), 
curcumin alone 50 () and 100 (∆) M for proliferation studies. 
Cell numbers have been calculated from cell lysate protein 
concentration by using Bradford assay (1mg protein= 4.7x106 
cells). 
 
Conclusions 
Apoferritin, without any further functionalization, can be 
proposed as a useful carrier of both therapeutics and imaging 
probes for MRI guided treatment of breast cancer cells 
characterized by an up-regulation of ferritin uptake. 
Furthermore, the access to the MRI approach can be exploited to 
get a better understanding of the role of ferritin receptor 
expression in the evolution of the pathologies in which the 
accumulation and release of this protein are involved. Finally, 
immune-SCARA5 detection on breast cancers cells could be 
recommended for the detection of this therapeutic marker 
exploitable for a selective drug delivery.  
Experimental 
Gd-HPDO3A (Prohance) was kindly provided by Bracco 
Imaging S.p.A (Milan, Italy). Apoferritin, Ferritin (from equine 
spleen), curcumin and all other chemicals were purchased from 
Sigma-Aldrich (St. Louis, MO). Water proton T1 and T2 
measurements were carried out on a Stelar SpinMaster 
spectrometer operating in the range from 20 to 80 MHz, by 
means of the inversion−recovery method (16 experiments, two 
scans) and Carr Purcell Meiboom Gill Sequence (CPMG) for T1 
and T2 measurements, respectively. The reproducibility of the T1 
data was ±0.5%. The final Fe, Gd and Mn concentration was 
determined by inductively coupled plasma mass spectrometry 
(ICP-MS) (Element-2; Thermo-Finnigan, Rodano (MI), Italy). 
Sample digestion was performed with 2 ml of concentrated 
HNO3 (70%) under microwave heating (Milestone 
MicroSYNTH Microwave labstation). 
Mn loaded apoferritin (Mn-Apo). The Mn-Apo preparation 
was carried out as described previously27. Briefly, iron-free horse 
spleen apoferritin was reconstituted in the presence of MnCl2 
solution at pH = 9.0, under air. To avoid the fast oxidation of the 
Mn(II) ion, the apoferritin and Mn(II) were added into an N2-
saturated AMPSO [N-(1,1-dimethyl-2-hydroxyethyl)-3-amino-
2-hydroxypropanesulfonic acid] solution, which had been 
previously corrected to the desired pH. The protein and the 
Mn(II) solutions were added to reach 1x10–6 and 3x10–3 M 
concentration, respectively, corresponding to a loading of 3000 
Mn(II) ions per apoferritin molecule. After 1 week reaction time, 
the samples were treated for 4 h at 20 °C with TETA (1,4,8,11-
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid) to reduce 
Mn(III) to Mn(II) as well as to remove Mn(II) ions bound at the 
outer surface of the protein shell. The obtained Mn-Apo 
solutions were characterized in terms of protein concentration by 
means of the Bradford method, using bovine serum albumin as a 
standard. 
Gd-HPDO3A and curcumin loaded apoferritin (Gd-CUR-
APO)  
The loading of curcumin and Gd-HPDO3A in the iron free HoS-
apoferritin cavity was carried out as described previously22. 
Briefly, the dissociation of the apoferritin into its subunits was 
done by lowering the pH of the protein solution 4.1x10-6 M 
protein solution (10 mL)  to pH 2 using HCl 1 M and maintaining 
this low pH for about 15 min. Afterward, 50 μL of a curcumin 
solution in DMSO (200 mg/mL) and 2 mL Gd-HPDO3A 0.5 M 
have been added for every milliliter of apoferritin solution. 
Successively, the pH was adjusted to 7.4 using 1 M NaOH. The 
resulting solution was stirred at room temperature for 2 h and 
then, after centrifugation, purified by gel filtration (superdex 
G25 column, Amersham) and dialysis. The solution was then 
concentrated using Vivaspin centrifugal concentrators (50.000 
MWCO). At the end of this process the concentrations of the 
protein (Bradford method), curcumin, and Gd were measured. 
The curcumin concentration has been measured 
spectrophotometrically at 430 nm in ethanol. 
Cell lines. 
Human breast cancer cell lines (MDA-MB-231 and MCF-7) 
were obtained from ATCC. MDA-MB-231 cells were cultured 
in DMEM medium (Lonza) containing 10% (v/v) fetal bovine 
serum (FBS), 100U/ml penicillin, 100 U/ml streptomycin, 0.01% 
plasmocin (Invivogen) and 4mM L-glutamine. MCF-7 cells were 
cultured in EMEM medium (Lonza) containing 10% (v/v) FBS, 
100 U/ml penicillin and streptomycin, 1% (v/v) non-essential 
amino-acid,  1 mM Sodium Pyruvate, and 2 mM L-glutamine, 
and 0.01 mg/ml insulin. Cells were incubated at 37°C in a 
humidified atmosphere of 5% CO2. These cell lines were tested 
for mycoplasma (MycoAlertTM PLUS Mycoplasma Detection 
Kit, Lonza).  
Uptake experiments. 
For HoS-ferritin, Mn-APO, APO-CUR, Gd-CUR-Apo and HoS-
apoferritin uptake experiments MCF-7 and MDA-MB-231 were 
seeded at a density of 6x105 cells in a 25 cm3 culture flask and 
placed in a wet (37°C) 5% CO2 air atmosphere incubator. For the 
different experiments, at 24 h post seeding, the cells were 
incubated with increasing concentrations of the above mentioned 
ferritin and apoferritins. After 6 or 24 h of incubation, cells were 
washed three times with 10 ml ice-cold PBS, detached with 
trypsin/EDTA. Fe, Gd and Mn content in each cell line was 
determined by ICP-MS. For MRI analysis (see below) cells were 
transferred into glass capillaries. The protein concentration 
(proportional to the cell number) was determined from cell 
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lysates by the Bradford assay, using bovine serum albumin as a 
standard. 
MRI. All the MR images were acquired on a Bruker Avance300 
spectrometer (7 T) equipped with a Micro 2.5 microimaging 
probe (Bruker BioSpin, Ettlingen, Germany). In vitro: glass 
capillaries containing about 2x106 cells were placed in an agar 
phantom and MR imaging was performed by using a standard 
T1-weighted multislice spin-echo sequence 
(TR/TE/NEX=200/3.3/8 (Figure 4) and TR/TE/NEX=600/3.7/2 
(Figure 5), FOV=1.2 cm, NEX=number of excitations; 
FOV=field of view). The T1 relaxation times were calculated 
using a standard saturation recovery spin echo. T2-weighted MRI 
images were obtained using a RARE sequence protocol 
(TR/TE/NEX=5000:43:2).   
 
Proliferation assay. MCF-7 were seeded in a 25 cm3 culture 
flask at a density of 2.5x105 cells. After 24 h, different 
concentration of APO-CUR, free apoferritin, free curcumin 
dissolved in DMSO, or DMSO alone were added and at 24, 48 
and 72 h post incubation, the media were removed and the cells 
washed 3 times with 5 ml PBS. Cells were then treated with 
trypsin for 5min at 37° C, transferred in 15 ml falcon tubes, and 
centrifuged at 1100 rpm per 5min. The supernatants were 
discarded and cells washed with PBS. At the end cell pellets were 
resuspended in 200 μl PBS, sonicated, and protein concentration 
were determined by the Bradford method. 1 mg of proteins 
correspond to 4.7x106 cells.  
 
Scara5 detection. 
For Scara5 detection, 3x105 MCF-7 and MDA-MB-231 were 
plated on glass coverslips and left to adhere overnight at 37°C in 
a 5% CO2 incubator. Then, cells were fixed with 4% formalin 
solution in PBS (Sigma-Aldrich) for 10 min at room temperature 
and washed twice with PBS. Cells were then rinsed twice with 
PBS and non-specific binding was blocked with 10% bovine 
serum albumin (BSA, from Sigma-Aldrich) in PBS for 20 min at 
room temperature. Anti-SCARA5 antibody (Thermo 
Scientific™ Pierce™) was diluted 1/50 in PBS containing 1% 
BSA and added to the coverslips for 1 hour at room temperature. 
Cells were rinsed twice with PBS and then incubated with Alexa 
Texas Red-conjugated goat anti-rabbit (life Technologies; 
1/1000 and Molecular Probes; 1/1000) in PBS containing 1% 
BSA for 1 hour at room temperature. Cells were rinsed three 
times with PBS and air dried. Cell nuclei were counterstained 
with DAPI. Coverslips were mounted with Fluoromount 
mounting medium (Sigma-Aldrich) and visualized with an 
Apotome fluorescent microscope (Leica). Photographs were 
taken using a digital CCD camera and images were processed 
using the AxioVision (Zeiss, V. 4.4), Adobe Photoshop and 
Microsoft PowerPoint software. Software program Image J was 
used to quantify fluorescence intensity. 
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